NCT02186002View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Healthy
Interventions
DRUG

ACT-451840 10 mg

ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water

DRUG

ACT-451840 50 mg

ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water

DRUG

ACT-451840 200 mg

ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water

DRUG

ACT-451840 500 mg

ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water

DRUG

ACT-451840 1000 mg

ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water

DRUG

ACT-451840 (Dose to be determined)

ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water

DRUG

Placebo

Trial Locations (1)

38610

OPTIMED Clinical Research, Gières

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT02186002 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A) | Biotech Hunter | Biotech Hunter